Note:
This article is licensed under a Creative Commons
Attribution-NonCommercial-ShareAlike 4.0 International License,
which permits any non-commercial use, sharing, adaptation,
distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if
changes were made. If you remix, transform, or build upon this article
or a part thereof, you must distribute your contributions under the same
license as the original. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by-nc-sa/4.0/.
Citation:
Ludwig, H. (Heinz); Delforge, M. (M.); Facon, T. (Thierry); et al. "Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network". Leukemia. 32, 2018, 1542 - 1560